ATRC

NEUTRALAnalyst

AtriCure, Inc.

2026-09-24

Price

$60.77

+1.36%

This is the 2026-09-24 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score2.2Noise

Signals4/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

AtriCure (ATRC) is demonstrating High-Conviction Price Discovery, surging to fresh 52-week highs on the back of multiple analyst upgrades and strong clinical momentum. The convergence of PERFECT_STACK and MARKET_LEADER technical signals aligns seamlessly with recent target hikes from Stifel and Needham, reflecting aggressive institutional absorption of the stock's growth narrative. Furthermore, the underlying RISK_ON macro regime—anchored by exceptionally tight high-yield credit spreads and a dropping VIX—provides an ideal liquidity environment for high-multiple medical device equities to thrive despite sensationalized macro anxieties.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISHEXTENSION

Key Takeaways

Actionable Thesis: Ride the breakout momentum in ATRC, supported by a GOLDEN_CROSS and a cluster of recent analyst price target hikes up to $65.
Key Risk: Valuation friction; the stock is trading at a premium EV/Sales multiple, leaving it vulnerable to profit-taking if competitor pulsed-field ablation devices gain market share.
What to Watch: Maintain $48.35 as a strict structural support level, while monitoring adoption rates tied to the new Society of Thoracic Surgeons quality measure.

← Back to 2026-09-24 View Full ATRC History →Yahoo Finance &nearr;